Evidence map›Paper›PMID 38723244›Full record

ArticleEpigenetics2024

Zishan Zang, Yifei Yin, Chunlan Liu, Qiang Zhu, Xuandong Huang, Hong Li, Rongxi Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zishan ZangDepartment of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
Yifei YinDepartment of Thyroid and Breast Surgery, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huaian, China.
Chunlan LiuDepartment of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
Qiang ZhuDepartment of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
Xuandong HuangDepartment of Thyroid and Breast Surgery, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huaian, China.
Hong LiDepartment of Pathology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huaian, China.
Rongxi YangDepartment of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.ORCID 0000-0002-6655-1986

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some benign and malignant breast tumours are similar in pathological morphology, which are difficult to be distinguished in clinical diagnosis. In this study, we intended to explore novel biomarkers for differential diagnosis of benign and malignant breast tumours. Methylation EPIC 850K beadchip and RNA-sequencing were used to analyse 29 tissue samples from patients with early-stage breast cancer (BC) and benign breast tumours for differently methylated and expressed genes. The altered methylation of

Indexed as

Biomarkers, TumorBreast NeoplasmsDNA MethylationDiagnosis, DifferentialFemaleHumansInterleukin-21 Receptor alpha SubunitReceptors, InterleukinBiomarkers, TumorIL21R protein, humanInterleukin-21 Receptor alpha SubunitReceptors, Interleukinbenign breast tumoursbiomarkerBreast cancerdifferential diagnosisDNA methylationIL21R gene

Identifiers

PMID38723244
PMCPMC11086039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.